5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
infections O
- O
do O
not O
give O
REMICADE O
during O
an O
active O
infection O
. O

If O
an O
infection O
develops O
, O
monitor O
carefully O
and O
stop O
REMICADE O
if O
infection O
becomes O
serious O
. O

( O
5.1 O
) O
* O
Invasive O
fungal O
infections O
- O
for O
patients O
who O
develop O
a O
systemic O
illness O
on O
REMICADE O
, O
consider O
empiric O
antifungal O
therapy O
for O
those O
who O
reside O
or O
travel O
to O
regions O
where O
mycoses O
are O
endemic O
( O
5.1 O
) O
* O
Malignancies O
- O
the O
incidence O
of O
malignancies O
, O
including O
invasive O
cervical O
cancer O
and O
lymphoma O
, O
was O
greater O
in O
REMICADE O
treated O
patients O
than O
in O
controls O
. O

Due O
to O
the O
risk O
of O
HSTCL O
carefully O
assess O
the O
risk/benefit O
especially O
if O
the O
patient O
has O
Crohn O
's O
disease O
or O
ulcerative O
colitis O
, O
is O
male O
, O
and O
is O
receiving O
azathioprine O
or O
6-mercaptopurine O
treatment O
. O

( O
5.2 O
) O
* O
Hepatitis O
B O
virus O
reactivation O
- O
test O
for O
HBV O
infection O
before O
starting O
REMICADE O
. O

Monitor O
HBV O
carriers O
during O
and O
several O
months O
after O
therapy O
. O

If O
reactivation O
occurs O
, O
stop O
REMICADE O
and O
begin O
anti-viral O
therapy O
. O

( O
5.3 O
) O
* O
Hepatotoxicity O
- O
severe O
hepatic O
reactions O
, O
some O
fatal O
or O
necessitating O
liver O
transplantation O
. O

Stop O
REMICADE O
in O
cases O
of O
jaundice O
and/or O
marked O
liver O
enzyme O
elevations O
. O

( O
5.4 O
) O
* O
Heart O
failure O
- O
new O
onset O
or O
worsening O
symptoms O
may O
occur O
. O

( O
4 O
, O
5.5 O
) O
* O
Cytopenias O
- O
advise O
patients O
to O
seek O
immediate O
medical O
attention O
if O
signs O
and O
symptoms O
develop O
, O
and O
consider O
stopping O
REMICADE O
. O

( O
5.6 O
) O
* O
Hypersensitivity O
- O
serious O
infusion O
reactions O
including O
anaphylaxis O
or O
serum O
sickness-like O
reactions O
may O
occur O
. O

( O
5.7 O
) O
* O
Cardiovascular O
and O
Cerebrovascular O
Reactions O
- O
Cerebrovascular O
accidents O
, O
myocardial O
infarctions O
( O
some O
fatal O
) O
, O
and O
arrhythmias O
have O
been O
reported O
during O
and O
within O
24 O
hours O
of O
initiation O
of O
REMICADE O
infusion O
. O

Monitor O
patients O
during O
REMICADE O
infusion O
and O
if O
serious O
reaction O
occurs O
, O
discontinue O
infusion O
. O

( O
5.8 O
) O
* O
Demyelinating O
disease O
- O
exacerbation O
or O
new O
onset O
may O
occur O
. O

( O
5.9 O
) O
* O
Lupus-like O
syndrome O
- O
stop O
REMICADE O
if O
syndrome O
develops O
. O

( O
5.14 O
) O
* O
Live O
vaccines O
or O
therapeutic O
infectious O
agents O
- O
should O
not O
be O
given O
with O
REMICADE O
. O

Bring O
pediatric O
patients O
up O
to O
date O
with O
all O
vaccinations O
prior O
to O
initiating O
REMICADE O
. O

At O
least O
a O
six O
month O
waiting O
period O
following O
birth O
is O
recommended O
before O
the O
administration O
of O
live O
vaccines O
to O
infants O
exposed O
in O
utero O
to O
infliximab O
( O
5.15 O
) O
5.1 O
Serious O
Infections O
Patients O
treated O
with O
REMICADE O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
involving O
various O
organ O
systems O
and O
sites O
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
. O

Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due O
to O
bacterial O
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
or O
parasitic O
organisms O
including O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
histoplasmosis B-OSE_Labeled_AE
, O
legionellosis B-OSE_Labeled_AE
, O
listeriosis B-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
and O
tuberculosis B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF-blockers O
. O

Patients O
have O
frequently O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
. O

Treatment O
with O
REMICADE O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active O
infection B-Not_AE_Candidate
, O
including O
clinically O
important O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Patients O
greater O
than O
65 O
years O
of O
age O
, O
patients O
with O
co-morbid O
conditions O
and/or O
patients O
taking O
concomitant O
immunosuppressants O
such O
as O
corticosteroids O
or O
methotrexate O
may O
be O
at O
greater O
risk O
of O
infection B-NonOSE_AE
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
: O
* O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
; O
* O
who O
have O
been O
exposed B-Not_AE_Candidate
to I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
; O
* O
with O
a O
history O
of O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
; O
* O
who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-NonOSE_AE
or O
endemic B-NonOSE_AE
mycoses I-NonOSE_AE
, O
such O
as O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
or O
blastomycosis B-NonOSE_AE
; O
or O
* O
with O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them I-Not_AE_Candidate
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Tuberculosis O
Cases O
of O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
or O
new O
tuberculosis B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
REMICADE O
, O
including O
patients O
who O
have O
previously O
received O
treatment O
for O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
. O

Cases O
of O
active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
have O
also O
occurred O
in O
patients O
being O
treated O
with O
REMICADE O
during O
treatment O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
. O

Patients O
should O
be O
evaluated O
for O
tuberculosis B-NonOSE_AE
risk O
factors O
and O
tested O
for O
latent B-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
REMICADE O
and O
periodically O
during O
therapy O
. O

Treatment O
of O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
therapy O
with O
TNF O
blocking O
agents O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
tuberculosis B-NonOSE_AE
reactivation I-NonOSE_AE
during O
therapy O
. O

Induration O
of O
5 O
mm O
or O
greater O
with O
tuberculin B-NonOSE_AE
skin I-NonOSE_AE
testing I-NonOSE_AE
should O
be O
considered O
a O
positive I-NonOSE_AE
test O
result O
when O
assessing O
if O
treatment O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
is O
needed O
prior O
to O
initiating O
REMICADE O
, O
even O
for O
patients O
previously O
vaccinated O
with O
Bacille B-NonOSE_AE
Calmette I-NonOSE_AE
- I-NonOSE_AE
Guerin I-NonOSE_AE
( I-NonOSE_AE
BCG I-NonOSE_AE
) O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
should O
also O
be O
considered O
prior O
to O
initiation O
of O
REMICADE O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative B-Not_AE_Candidate
test I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
but O
having O
risk O
factors O
for O
tuberculosis B-NonOSE_AE
infection I-NonOSE_AE
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
is O
appropriate O
for O
an O
individual O
patient O
. O

Tuberculosis B-NonOSE_AE
should O
be O
strongly O
considered O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
during O
REMICADE O
treatment O
, O
especially O
in O
patients O
who O
have O
previously O
or O
recently O
traveled O
to O
countries O
with O
a O
high O
prevalence O
of O
tuberculosis B-NonOSE_AE
, O
or O
who O
have O
had O
close O
contact O
with O
a O
person O
with O
active B-NonOSE_AE
tuberculosis I-NonOSE_AE
. O

Monitoring O
Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
REMICADE O
, O
including O
the O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested B-Not_AE_Candidate
negative I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
. O

Tests B-NonOSE_AE
for I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
may O
also O
be O
falsely I-NonOSE_AE
negative I-NonOSE_AE
while O
on O
therapy O
with O
REMICADE O
. O

REMICADE O
should O
be O
discontinued O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
or O
sepsis B-NonOSE_AE
. O

A O
patient O
who O
develops O
a O
new O
infection B-NonOSE_AE
during O
treatment O
with O
REMICADE O
should O
be O
closely O
monitored O
, O
undergo O
a O
prompt O
and O
complete O
diagnostic O
workup O
appropriate O
for O
an O
immunocompromised B-Not_AE_Candidate
patient O
, O
and O
appropriate O
antimicrobial O
therapy O
should O
be O
initiated O
. O

Invasive O
Fungal O
Infections O
For O
patients O
who O
reside O
or O
travel O
in O
regions O
where O
mycoses B-NonOSE_AE
are O
endemic O
, O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
should O
be O
suspected O
if O
they O
develop O
a O
serious O
systemic O
illness B-NonOSE_AE
. O

Appropriate O
empiric O
antifungal O
therapy O
should O
be O
considered O
while O
a O
diagnostic O
workup O
is O
being O
performed O
. O

Antigen B-NonOSE_AE
and I-NonOSE_AE
antibody I-NonOSE_AE
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

When O
feasible O
, O
the O
decision O
to O
administer O
empiric O
antifungal O
therapy O
in O
these O
patients O
should O
be O
made O
in O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
diagnosis O
and O
treatment O
of O
invasive O
fungal B-NonOSE_AE
infections I-NonOSE_AE
and O
should O
take O
into O
account O
both O
the O
risk O
for O
severe O
fungal B-NonOSE_AE
infection I-NonOSE_AE
and O
the O
risks O
of O
antifungal O
therapy O
. O

5.2 O
Malignancies O
Malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
among O
children O
, O
adolescents O
and O
young O
adults O
who O
received O
treatment O
with O
TNF-blocking O
agents O
( O
initiation O
of O
therapy O
< O
=18 O
years O
of O
age O
) O
, O
including O
REMICADE O
. O

Approximately O
half O
of O
these O
cases O
were O
lymphomas B-OSE_Labeled_AE
, O
including O
Hodgkin B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
and O
non-Hodgkin O
's O
lymphoma I-OSE_Labeled_AE
. O

The O
other O
cases O
represented O
a O
variety O
of O
malignancies B-OSE_Labeled_AE
, O
including O
rare O
malignancies B-OSE_Labeled_AE
that O
are O
usually O
associated O
with O
immunosuppression B-NonOSE_AE
and O
malignancies B-OSE_Labeled_AE
that O
are O
not O
usually O
observed O
in O
children O
and O
adolescents O
. O

The O
malignancies B-OSE_Labeled_AE
occurred O
after O
a O
median O
of O
30 O
months O
( O
range O
1 O
to O
84 O
months O
) O
after O
the O
first O
dose O
of O
TNF O
blocker O
therapy O
. O

Most O
of O
the O
patients O
were O
receiving O
concomitant O
immunosuppressants O
. O

These O
cases O
were O
reported O
post-marketing O
and O
are O
derived O
from O
a O
variety O
of O
sources O
, O
including O
registries O
and O
spontaneous O
postmarketing O
reports O
. O

Lymphomas O
In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
all O
the O
TNF-blocking O
agents O
, O
more O
cases O
of O
lymphoma B-OSE_Labeled_AE
have O
been O
observed O
among O
patients O
receiving O
a O
TNF O
blocker O
compared O
with O
control O
patients O
. O

In O
the O
controlled O
and O
open-label O
portions O
of O
REMICADE O
clinical O
trials O
, O
5 O
patients O
developed O
lymphomas B-OSE_Labeled_AE
among O
5707 O
patients O
treated O
with O
REMICADE O
( O
median O
duration O
of O
follow-up O
1.0 O
years O
) O
vs O
. O
0 O
lymphomas B-NonOSE_AE
in O
1600 O
control O
patients O
( O
median O
duration O
of O
follow-up O
0.4 O
years O
) O
. O

In O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
, O
2 O
lymphomas B-OSE_Labeled_AE
were O
observed O
for O
a O
rate O
of O
0.08 O
cases O
per O
100 O
patient-years O
of O
follow-up O
, O
which O
is O
approximately O
three-fold O
higher O
than O
expected O
in O
the O
general O
population O
. O

In O
the O
combined O
clinical O
trial O
population O
for O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
and O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
5 O
lymphomas B-OSE_Labeled_AE
were O
observed O
for O
a O
rate O
of O
0.10 O
cases O
per O
100 O
patient-years O
of O
follow-up O
, O
which O
is O
approximately O
four-fold O
higher O
than O
expected O
in O
the O
general O
population O
. O

Patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
or O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
particularly O
patients O
with O
highly O
active O
disease O
and/or O
chronic O
exposure O
to O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
, O
may O
be O
at O
a O
higher O
risk O
( O
up O
to O
several O
fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
lymphoma B-NonOSE_AE
, O
even O
in O
the O
absence O
of O
TNF-blocking O
therapy O
. O

Cases O
of O
acute B-OSE_Labeled_AE
and O
chronic O
leukemia I-OSE_Labeled_AE
have O
been O
reported O
with O
postmarketing O
TNF-blocker O
use O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
other O
indications O
. O

Even O
in O
the O
absence O
of O
TNF O
blocker O
therapy O
, O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
may O
be O
at O
a O
higher O
risk O
( O
approximately O
2-fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
leukemia B-NonOSE_AE
. O

Hepatosplenic O
T-cell O
Lymphoma O
( O
HSTCL O
) O
Postmarketing O
cases O
of O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphoma I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HSTCL I-OSE_Labeled_AE
) O
, O
a O
rare O
type O
of O
T B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blockers O
including O
REMICADE O
. O

These O
cases O
have O
had O
a O
very O
aggressive O
disease O
course O
and O
have O
been O
fatal B-NonOSE_AE
. O

Almost O
all O
patients O
had O
received O
treatment O
with O
the O
immunosuppressants O
azathioprine O
or O
6-mercaptopurine O
concomitantly O
with O
a O
TNF-blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
majority O
of O
reported O
REMICADE O
cases O
have O
occurred O
in O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
and O
most O
were O
in O
adolescent O
and O
young O
adult O
males O
. O

It O
is O
uncertain O
whether O
the O
occurrence O
of O
HSTCL B-NonOSE_AE
is O
related O
to O
TNF-blockers O
or O
TNF-blockers O
in O
combination O
with O
these O
other O
immunosuppressants O
. O

When O
treating O
patients O
, O
consideration O
of O
whether O
to O
use O
REMICADE O
alone O
or O
in O
combination O
with O
other O
immunosuppressants O
such O
as O
azathioprine O
or O
6-mercaptopurine O
should O
take O
into O
account O
a O
possibility O
that O
there O
is O
a O
higher O
risk O
of O
HSTCL B-NonOSE_AE
with O
combination O
therapy O
versus O
an O
observed O
increased O
risk O
of O
immunogenicity B-NonOSE_AE
and O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
with O
REMICADE O
monotherapy O
from O
the O
clinical O
trial O
data O
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Skin B-OSE_Labeled_AE
Cancer I-OSE_Labeled_AE
Melanoma B-OSE_Labeled_AE
and O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
TNF O
blocker O
therapy O
, O
including O
REMICADE O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Periodic O
skin O
examination O
is O
recommended O
for O
all O
patients O
, O
particularly O
those O
with O
risk O
factors O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

Cervical O
Cancer O
A O
population-based O
retrospective O
cohort O
study O
using O
data O
from O
Swedish O
national O
health O
registries O
found O
a O
2 O
to O
3 O
fold O
increase O
in O
the O
incidence O
of O
invasive O
cervical B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
in O
women O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
treated O
with O
infliximab O
compared O
to O
biologics-naive O
patients O
or O
the O
general O
population O
, O
particularly O
those O
over O
60 O
years O
of O
age O
. O

A O
causal O
relationship O
between O
infliximab O
and O
cervical B-NonOSE_AE
cancer I-NonOSE_AE
can O
not O
be O
excluded O
. O

Periodic O
screening O
should O
continue O
in O
women O
treated O
with O
REMICADE O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Other O
Malignancies O
In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
some O
TNF-blocking O
agents O
including O
REMICADE O
, O
more O
malignancies B-OSE_Labeled_AE
( O
excluding O
lymphoma B-NonOSE_AE
and O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
[ I-NonOSE_AE
NMSC I-NonOSE_AE
] O
) O
have O
been O
observed O
in O
patients O
receiving O
those O
TNF-blockers O
compared O
with O
control O
patients O
. O

During O
the O
controlled O
portions O
of O
REMICADE O
trials O
in O
patients O
with O
moderately O
to O
severely O
active O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
psoriatic B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
ankylosing B-Not_AE_Candidate
spondylitis I-Not_AE_Candidate
, O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
, O
and O
plaque B-Not_AE_Candidate
psoriasis I-Not_AE_Candidate
, O
14 O
patients O
were O
diagnosed O
with O
malignancies B-OSE_Labeled_AE
( O
excluding O
lymphoma B-NonOSE_AE
and O
NMSC B-NonOSE_AE
) O
among O
4019 O
REMICADE-treated O
patients O
vs O
. O
1 O
among O
1597 O
control O
patients O
( O
at O
a O
rate O
of O
0.52/100 O
patient-years O
among O
REMICADE-treated O
patients O
vs O
. O
a O
rate O
of O
0.11/100 O
patient-years O
among O
control O
patients O
) O
, O
with O
median O
duration O
of O
follow-up O
0.5 O
years O
for O
REMICADE-treated O
patients O
and O
0.4 O
years O
for O
control O
patients O
. O

Of O
these O
, O
the O
most O
common O
malignancies B-OSE_Labeled_AE
were O
breast I-OSE_Labeled_AE
, O
colorectal O
, O
and O
melanoma B-OSE_Labeled_AE
. O

The O
rate O
of O
malignancies B-NonOSE_AE
among O
REMICADE-treated O
patients O
was O
similar O
to O
that O
expected O
in O
the O
general O
population O
whereas O
the O
rate O
in O
control O
patients O
was O
lower O
than O
expected O
. O

In O
a O
clinical O
trial O
exploring O
the O
use O
of O
REMICADE O
in O
patients O
with O
moderate O
to O
severe O
chronic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
pulmonary I-Not_AE_Candidate
disease I-Not_AE_Candidate
( I-Not_AE_Candidate
COPD I-Not_AE_Candidate
) O
, O
more O
malignancies B-OSE_Labeled_AE
, O
the O
majority O
of O
lung O
or O
head O
and O
neck O
origin O
, O
were O
reported O
in O
REMICADE-treated O
patients O
compared O
with O
control O
patients O
. O

All O
patients O
had O
a O
history O
of O
heavy O
smoking O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Prescribers O
should O
exercise O
caution O
when O
considering O
the O
use O
of O
REMICADE O
in O
patients O
with O
moderate O
to O
severe O
COPD B-Not_AE_Candidate
. O

Psoriasis B-Not_AE_Candidate
patients O
should O
be O
monitored O
for O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancers I-NonOSE_AE
( I-NonOSE_AE
NMSCs I-NonOSE_AE
) O
, O
particularly O
those O
patients O
who O
have O
had O
prior O
prolonged O
phototherapy O
treatment O
. O

In O
the O
maintenance O
portion O
of O
clinical O
trials O
for O
REMICADE O
, O
NMSCs B-OSE_Labeled_AE
were O
more O
common O
in O
patients O
with O
previous O
phototherapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
potential O
role O
of O
TNF-blocking O
therapy O
in O
the O
development O
of O
malignancies B-NonOSE_AE
is O
not O
known O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Rates O
in O
clinical O
trials O
for O
REMICADE O
can O
not O
be O
compared O
to O
rates O
in O
clinical O
trials O
of O
other O
TNF-blockers O
and O
may O
not O
predict O
rates O
observed O
in O
a O
broader O
patient O
population O
. O

Caution O
should O
be O
exercised O
in O
considering O
REMICADE O
treatment O
in O
patients O
with O
a O
history O
of O
malignancy B-Not_AE_Candidate
or O
in O
continuing O
treatment O
in O
patients O
who O
develop O
malignancy B-NonOSE_AE
while O
receiving O
REMICADE O
. O

5.3 O
Hepatitis O
B O
Virus O
Reactivation O
Use O
of O
TNF O
blockers O
, O
including O
REMICADE O
, O
has O
been O
associated O
with O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) O
in O
patients O
who O
are O
chronic O
carriers O
of O
this O
virus O
. O

In O
some O
instances O
, O
HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
occurring O
in O
conjunction O
with O
TNF O
blocker O
therapy O
has O
been O
fatal B-NonOSE_AE
. O

The O
majority O
of O
these O
reports O
have O
occurred O
in O
patients O
concomitantly O
receiving O
other O
medications B-NonOSE_AE
that I-NonOSE_AE
suppress I-NonOSE_AE
the I-NonOSE_AE
immune I-NonOSE_AE
system I-NonOSE_AE
, O
which O
may O
also O
contribute O
to O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
should O
be O
tested O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
before O
initiating O
TNF O
blocker O
therapy O
, O
including O
REMICADE O
. O

For O
patients O
who O
test B-Not_AE_Candidate
positive I-Not_AE_Candidate
for I-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
, O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
is O
recommended O
. O

Adequate O
data O
are O
not O
available O
on O
the O
safety O
or O
efficacy O
of O
treating O
patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
with O
anti-viral O
therapy O
in O
conjunction O
with O
TNF O
blocker O
therapy O
to O
prevent O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
and O
require O
treatment O
with O
TNF O
blockers O
should O
be O
closely O
monitored O
for O
clinical O
and O
laboratory O
signs O
of O
active O
HBV B-NonOSE_AE
infection I-NonOSE_AE
throughout O
therapy O
and O
for O
several O
months O
following O
termination O
of O
therapy O
. O

In O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
, O
TNF O
blockers O
should O
be O
stopped O
and O
antiviral O
therapy O
with O
appropriate O
supportive O
treatment O
should O
be O
initiated O
. O

The O
safety O
of O
resuming O
TNF O
blocker O
therapy O
after O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
controlled O
is O
not O
known O
. O

Therefore O
, O
prescribers O
should O
exercise O
caution O
when O
considering O
resumption O
of O
TNF O
blocker O
therapy O
in O
this O
situation O
and O
monitor O
patients O
closely O
. O

5.4 O
Hepatotoxicity B-OSE_Labeled_AE
Severe O
hepatic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
and O
cholestasis B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
postmarketing O
data O
in O
patients O
receiving O
REMICADE O
. O

Autoimmune B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
has O
been O
diagnosed O
in O
some O
of O
these O
cases O
. O

Severe O
hepatic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
between O
2 O
weeks O
to O
more O
than O
1 O
year O
after O
initiation O
of O
REMICADE O
; O
elevations B-NonOSE_AE
in I-NonOSE_AE
hepatic I-NonOSE_AE
aminotransferase I-NonOSE_AE
levels I-NonOSE_AE
were O
not O
noted O
prior O
to O
discovery O
of O
the O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
in O
many O
of O
these O
cases O
. O

Some O
of O
these O
cases O
were O
fatal B-NonOSE_AE
or O
necessitated O
liver B-NonOSE_AE
transplantation I-NonOSE_AE
. O

Patients O
with O
symptoms O
or O
signs O
of O
liver B-NonOSE_AE
dysfunction I-NonOSE_AE
should O
be O
evaluated O
for O
evidence O
of O
liver B-NonOSE_AE
injury I-NonOSE_AE
. O

If O
jaundice B-NonOSE_AE
and/or O
marked O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevations I-NonOSE_AE
( O
e.g. O
, O
> O
=5 O
times O
the O
upper O
limit O
of O
normal O
) O
develop O
, O
REMICADE O
should O
be O
discontinued O
, O
and O
a O
thorough O
investigation O
of O
the O
abnormality O
should O
be O
undertaken O
. O

In O
clinical O
trials O
, O
mild O
or O
moderate O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT O
and O
AST I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
REMICADE O
without O
progression O
to O
severe O
hepatic B-NonOSE_AE
injury I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Patients O
with O
Heart O
Failure O
REMICADE O
has O
been O
associated O
with O
adverse O
outcomes O
in O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
and O
should O
be O
used O
in O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
only O
after O
consideration O
of O
other O
treatment O
options O
. O

The O
results O
of O
a O
randomized O
study O
evaluating O
the O
use O
of O
REMICADE O
in O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
( I-Not_AE_Candidate
NYHA I-Not_AE_Candidate
Functional I-Not_AE_Candidate
Class I-Not_AE_Candidate
III I-Not_AE_Candidate
/IV O
) O
suggested O
higher O
mortality B-NonOSE_AE
in O
patients O
who O
received O
10 O
mg/kg O
REMICADE O
, O
and O
higher O
rates O
of O
cardiovascular B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
at O
doses O
of O
5 O
mg/kg O
and O
10 O
mg/kg O
. O

There O
have O
been O
post-marketing O
reports O
of O
worsening B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
with O
and O
without O
identifiable O
precipitating O
factors O
, O
in O
patients O
taking O
REMICADE O
. O

There O
have O
also O
been O
post-marketing O
reports O
of O
new O
onset O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
including O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
without O
known O
pre-existing O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Some O
of O
these O
patients O
have O
been O
under O
50 O
years O
of O
age O
. O

If O
a O
decision O
is O
made O
to O
administer O
REMICADE O
to O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
they O
should O
be O
closely O
monitored O
during O
therapy O
, O
and O
REMICADE O
should O
be O
discontinued O
if O
new O
or O
worsening O
symptoms O
of O
heart B-NonOSE_AE
failure I-NonOSE_AE
appear O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Hematologic O
Reactions O
Cases O
of O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
and O
pancytopenia B-OSE_Labeled_AE
, O
some O
with O
a O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
in O
patients O
receiving O
REMICADE O
. O

The O
causal O
relationship O
to O
REMICADE O
therapy O
remains O
unclear O
. O

Although O
no O
high-risk O
group O
( O
s O
) O
has O
been O
identified O
, O
caution O
should O
be O
exercised O
in O
patients O
being O
treated O
with O
REMICADE O
who O
have O
ongoing O
or O
a O
history O
of O
significant O
hematologic B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
. O

All O
patients O
should O
be O
advised O
to O
seek O
immediate O
medical O
attention O
if O
they O
develop O
signs O
and O
symptoms O
suggestive O
of O
blood B-NonOSE_AE
dyscrasias I-NonOSE_AE
or O
infection B-NonOSE_AE
( O
e.g. O
, O
persistent O
fever B-NonOSE_AE
) O
while O
on O
REMICADE O
. O

Discontinuation O
of O
REMICADE O
therapy O
should O
be O
considered O
in O
patients O
who O
develop O
significant O
hematologic B-NonOSE_AE
abnormalities I-NonOSE_AE
. O

5.7 O
Hypersensitivity O
REMICADE O
has O
been O
associated O
with O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
that O
vary O
in O
their O
time O
of O
onset O
and O
required O
hospitalization O
in O
some O
cases O
. O

Most O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
which O
include O
anaphylaxis B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and/or O
hypotension B-OSE_Labeled_AE
, O
have O
occurred O
during O
or O
within O
2 O
hours O
of O
REMICADE O
infusion O
. O

However O
, O
in O
some O
cases O
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
after O
initial O
REMICADE O
therapy O
( O
i.e. O
, O
as O
early O
as O
after O
the O
second O
dose O
) O
, O
and O
when O
REMICADE O
therapy O
was O
reinstituted O
following O
an O
extended O
period O
without O
REMICADE O
treatment O
. O

Symptoms O
associated O
with O
these O
reactions O
include O
fever B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
sore B-NonOSE_AE
throat I-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
polyarthralgias B-NonOSE_AE
, O
hand B-NonOSE_AE
and O
facial O
edema I-NonOSE_AE
and/or O
dysphagia B-NonOSE_AE
. O

These O
reactions O
were O
associated O
with O
a O
marked O
increase O
in O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
, O
loss O
of O
detectable O
serum O
concentrations O
of O
infliximab O
, O
and O
possible O
loss O
of O
drug O
efficacy O
. O

REMICADE O
should O
be O
discontinued O
for O
severe O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
. O

Medications O
for O
the O
treatment O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
acetaminophen O
, O
antihistamines O
, O
corticosteroids O
and/or O
epinephrine O
) O
should O
be O
available O
for O
immediate O
use O
in O
the O
event O
of O
a O
reaction O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
, O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
psoriasis B-Not_AE_Candidate
clinical O
trials O
, O
re-administration O
of O
REMICADE O
after O
a O
period O
of O
no O
treatment O
resulted O
in O
a O
higher O
incidence O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
relative O
to O
regular O
maintenance O
treatment O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
general O
, O
the O
benefit-risk O
of O
re-administration O
of O
REMICADE O
after O
a O
period O
of O
no-treatment O
, O
especially O
as O
a O
re-induction O
regimen O
given O
at O
weeks O
0 O
, O
2 O
and O
6 O
, O
should O
be O
carefully O
considered O
. O

In O
the O
case O
where O
REMICADE O
maintenance O
therapy O
for O
psoriasis B-Not_AE_Candidate
is O
interrupted O
, O
REMICADE O
should O
be O
reinitiated O
as O
a O
single O
dose O
followed O
by O
maintenance O
therapy O
. O

5.8 O
Cardiovascular O
and O
Cerebrovascular O
Reactions O
During O
and O
After O
Infusion O
Serious O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia/ O
infarction I-OSE_Labeled_AE
( O
some O
fatal B-NonOSE_AE
) O
, O
hypotension B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
and O
arrhythmias B-OSE_Labeled_AE
have O
been O
reported O
during O
and O
within O
24 O
hours O
of O
initiation O
of O
REMICADE O
infusion O
. O

Cases O
of O
transient B-OSE_Labeled_AE
visual I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
have O
been O
reported O
during O
or O
within O
2 O
hours O
of O
infusion O
of O
REMICADE O
. O

Monitor O
patients O
during O
infusion O
and O
if O
serious O
reaction O
occurs O
, O
discontinue O
infusion O
. O

Further O
management O
of O
reactions O
should O
be O
dictated O
by O
signs O
and O
symptoms O
[ O
See O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.9 O
Neurologic O
Reactions O
REMICADE O
and O
other O
agents O
that O
inhibit O
TNF O
have O
been O
associated O
with O
CNS O
manifestation O
of O
systemic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
seizure B-OSE_Labeled_AE
and O
new O
onset O
or O
exacerbation O
of O
clinical O
symptoms O
and/or O
radiographic O
evidence O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
and O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Prescribers O
should O
exercise O
caution O
in O
considering O
the O
use O
of O
REMICADE O
in O
patients O
with O
these O
neurologic B-NonOSE_AE
disorders I-NonOSE_AE
and O
should O
consider O
discontinuation O
of O
REMICADE O
if O
these O
disorders O
develop O
. O

5.10 O
Use O
with O
Anakinra O
Serious O
infections B-NonOSE_AE
and O
neutropenia B-NonOSE_AE
were O
seen O
in O
clinical O
studies O
with O
concurrent O
use O
of O
anakinra O
and O
another O
TNFalpha-blocking O
agent O
, O
etanercept O
, O
with O
no O
added O
clinical O
benefit O
compared O
to O
etanercept O
alone O
. O

Because O
of O
the O
nature O
of O
the O
adverse O
reactions O
seen O
with O
the O
combination O
of O
etanercept O
and O
anakinra O
therapy O
, O
similar O
toxicities O
may O
also O
result O
from O
the O
combination O
of O
anakinra O
and O
other O
TNFalpha-blocking O
agents O
. O

Therefore O
, O
the O
combination O
of O
REMICADE O
and O
anakinra O
is O
not O
recommended O
. O

5.11 O
Use O
with O
Abatacept O
In O
clinical O
studies O
, O
concurrent O
administration O
of O
TNF-blocking O
agents O
and O
abatacept O
have O
been O
associated O
with O
an O
increased O
risk O
of O
infections B-NonOSE_AE
including O
serious O
infections B-NonOSE_AE
compared O
with O
TNF O
- O
blocking O
agents O
alone O
, O
without O
increased O
clinical O
benefit O
. O

Therefore O
, O
the O
combination O
of O
REMICADE O
and O
abatacept O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.12 O
Concurrent O
Administration O
with O
Other O
Biological O
Therapeutics O
There O
is O
insufficient O
information O
regarding O
the O
concomitant O
use O
of O
REMICADE O
with O
other O
biological O
therapeutics O
used O
to O
treat O
the O
same O
conditions O
as O
REMICADE O
. O

The O
concomitant O
use O
of O
REMICADE O
with O
these O
biologics O
is O
not O
recommended O
because O
of O
the O
possibility O
of O
an O
increased O
risk O
of O
infection B-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.13 O
Switching O
Between O
Biological O
Disease-Modifying O
Antirheumatic O
Drugs O
( O
DMARDs O
) O
Care O
should O
be O
taken O
when O
switching O
from O
one O
biologic O
to O
another O
, O
since O
overlapping O
biological O
activity O
may O
further O
increase O
the O
risk O
of O
infection B-NonOSE_AE
. O

5.14 O
Autoimmunity O
Treatment O
with O
REMICADE O
may O
result O
in O
the O
formation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
autoantibodies I-OSE_Labeled_AE
and O
in O
the O
development O
of O
a O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

If O
a O
patient O
develops O
symptoms O
suggestive O
of O
a O
lupus B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
syndrome I-NonOSE_AE
following O
treatment O
with O
REMICADE O
, O
treatment O
should O
be O
discontinued O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.15 O
Live O
Vaccines/Therapeutic O
Infectious O
Agents O
In O
patients O
receiving O
anti-TNF O
therapy O
, O
limited O
data O
are O
available O
on O
the O
response O
to O
vaccination O
with O
live O
vaccines O
or O
on O
the O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
by I-NonOSE_AE
live I-NonOSE_AE
vaccines I-NonOSE_AE
. O

Use O
of O
live O
vaccines O
can O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

The O
concurrent O
administration O
of O
live O
vaccines O
with O
REMICADE O
is O
not O
recommended O
. O

Fatal B-NonOSE_AE
outcome O
due O
to O
disseminated B-NonOSE_AE
BCG I-NonOSE_AE
infection I-NonOSE_AE
has O
been O
reported O
in O
an O
infant O
who O
received O
a O
BCG O
vaccine O
after O
in B-OSE_Labeled_AE
utero I-OSE_Labeled_AE
exposure I-OSE_Labeled_AE
to I-OSE_Labeled_AE
infliximab I-OSE_Labeled_AE
. O

Infliximab O
is O
known O
to O
cross O
the O
placenta O
and O
has O
been O
detected O
up O
to O
6 O
months O
following O
birth O
. O

At O
least O
a O
six O
month O
waiting O
period O
following O
birth O
is O
recommended O
before O
the O
administration O
of O
any O
live O
vaccine O
to O
infants O
exposed O
in O
utero O
to O
infliximab O
. O

Other O
uses O
of O
therapeutic O
infectious O
agents O
such O
as O
live O
attenuated O
bacteria O
( O
e.g. O
, O
BCG O
bladder O
instillation O
for O
the O
treatment O
of O
cancer B-Not_AE_Candidate
) O
could O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

It O
is O
recommended O
that O
therapeutic B-NonOSE_AE
infectious I-NonOSE_AE
agents I-NonOSE_AE
not O
be O
given O
concurrently O
with O
REMICADE O
. O

It O
is O
recommended O
that O
all O
pediatric O
patients O
be O
brought O
up O
to O
date O
with O
all O
vaccinations O
prior O
to O
initiating O
REMICADE O
therapy O
. O

The O
interval O
between O
vaccination O
and O
initiation O
of O
REMICADE O
therapy O
should O
be O
in O
accordance O
with O
current O
vaccination O
guidelines O
. O

